Abstracts Archive - Page 794 of 2607 - ACR Meeting Abstracts

Abstract Number: 1333 • ACR Convergence 2021
Guselkumab (TREMFYA®) Provides Consistent and Durable Pain Improvement in Patients with Active Psoriatic Arthritis: Results of 2 Phase 3, Randomized, Controlled Clinical Trials
Peter Nash¹, Lai-Shan Tam², Wen-Chan Tsai³, Ying-Ying Leung⁴, Daniel Furtner⁵, Shihong Sheng⁶, Yanli Wang⁶, May Shawi⁷, Alexa Kollmeier⁸, Jonathan Sherlock⁹ and Daniel Cua⁶, ¹Griffith University, Brisbane, Australia, ²Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China (People's Republic), ³Janssen Research & Development, LLC, Kaohsiung City, Taiwan (Republic of China), ⁴Singapore General Hospital and Duke-NUS Medical School, Singapore, Singapore, ⁵Janssen, a division of Johnson & Johnson Pte. Ltd., Singapore, Singapore, ⁶Janssen Research & Development, LLC, Spring House, PA, ⁷Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, ⁸Janssen Research & Development, LLC, La Jolla, CA, ⁹Janssen Research & Development, LLC and University of Oxford, Spring House, PA
Background/Purpose: Guselkumab (GUS), a targeted inhibitor of IL-23p19, demonstrated significant efficacy v placebo (PBO) in achieving ACR20 response at week (W) 24 in patients (pts)…
Abstract Number: 1334 • ACR Convergence 2021
How Does Gender Affect Secukinumab Treatment Outcomes and Retention Rates in Patients with Psoriatic Arthritis? – Real World Data from a German Observational Study
Uta Kiltz¹, Jan Brandt-Jrgens², Peter Kästner³, Elke Riechers⁴, Daniel Peterlik⁵ and Hans-Peter Tony⁶, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Rheumatologische Schwerpunktpraxis, Berlin, Germany, ³Ambulantes Rheumazentrum Erfurt, Erfurt, Germany, ⁴Department for Rheumatology and Immunology, Hannover Medical University, Hannover, ⁵Novartis Pharma GmbH, Nürnberg, Germany, ⁶Universitätsklinikum Würzburg, Wuerzburg, Germany
Background/Purpose: Gender disparities in PsA can affect natural course of disease, clinical presentation and response to medication1. The German non-interventional study AQUILA provides real-world data…
Abstract Number: 1335 • ACR Convergence 2021
Guselkumab Provides Sustained Domain-Specific and Comprehensive Efficacy as Assessed Using Composite Endpoints in Patients with Active Psoriatic Arthritis
Laura Coates¹, Christopher Ritchlin², Laure Gossec³, Philip S Helliwell⁴, Proton Rahman⁵, Elizabeth Hsia⁶, Alexa Kollmeier⁷, Xie Xu⁶, Chetan Karyekar⁸, May Shawi⁹, Wim Noel¹⁰, Yusang Jiang⁶, Shihong Sheng⁶, Yanli Wang⁶ and Philip Mease¹¹, ¹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, ³Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ⁶Janssen Research & Development, LLC, Spring House, PA, ⁷Janssen Research & Development, LLC, La Jolla, CA, ⁸Janssen R&D, Spring House, PA, ⁹Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, ¹⁰Janssen Pharmaceutica, Vilvoorde, Belgium, ¹¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA
Background/Purpose: Guselkumab (GUS) is a human monoclonal antibody specific to the p19-subunit of interleukin-23. GUS significantly improved signs and symptoms of PsA through Week 24,…
Abstract Number: 1336 • ACR Convergence 2021
Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19-Subunit of Interleukin-23, Through 2 Years: Results from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naïve Patients with Active Psoriatic Arthritis
Iain McInnes¹, Proton Rahman², Alice Gottlieb³, Elizabeth Hsia⁴, Alexa Kollmeier⁵, Xie Xu⁴, Shihong Sheng⁴, Yusang Jiang⁴, May Shawi⁶, Soumya Chakravarty⁷, Désirée van der Heijde⁸ and Philip Mease⁹, ¹University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom, ²Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ³Icahn School of Medicine at Mount Sinai, New York, NY, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Janssen Research & Development, LLC, La Jolla, CA, ⁶Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, ⁷Janssen Scientific Affairs, LLC and Drexel University College of Medicine, Horsham, PA, ⁸Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ⁹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA
Background/Purpose: Guselkumab (GUS), an anti-IL-23p19-subunit mAb dosed every 4 or 8 weeks (Q4W or Q8W), demonstrated efficacy for joint and skin symptoms, inhibition of structural…
Abstract Number: 1337 • ACR Convergence 2021
Long-Term Safety Data for IL-12/23 Inhibitor (Ustekinumab) or Tumor Necrosis Factor Inhibitor in Patients with Psoriatic Arthritis from a Real-World Study
Stefan Siebert¹, Paul Bergmans², Kurt de Vlam³, Elisa Gremese⁴, Beatriz Joven-Ibáñez⁵, Tatiana Korotaeva⁶, Wim Noël⁷, Michael Nurmohamed⁸, Petros Sfikakis⁹, Elke Theander¹⁰, Laure Gossec¹¹ and Josef Smolen¹², ¹University of Glasgow, Glasgow, United Kingdom, ²Janssen-Cilag BV, Breda, Netherlands, ³University Hospitals Leuven, Leuven, Belgium, ⁴Fondazione Policlinico A Gemelli-IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy, ⁵University Hospital 12 de Octubre, Madrid, Spain, ⁶VA Nasonova Research Institute of Rheumatology, Moscow, Russia, ⁷Janssen Pharmaceutica, HEMAR Department, Beerse, Belgium, ⁸Reade and Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands, ⁹National Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, ¹⁰Janssen Cilag, Lund, Sweden, ¹¹Sorbonne Université; APHP, Rheumatology Department, Pitié-Salpêtrière Hospital, Paris, France, ¹²Medical University of Vienna, Vienna, Austria
Background/Purpose: Psoriasis and PsA are associated with multiple comorbidities such as cardiovascular disease and metabolic syndrome. These comorbidities may render patients prone to developing adverse…
Abstract Number: 1338 • ACR Convergence 2021
Bimekizumab in Patients with Psoriatic Arthritis: 3-Year Results for Overall and Tumor Necrosis Factor Inhibitor (TNFi)-Naïve Populations from a Phase 2b Open-Label Extension Study
Philip Mease¹, Atul Deodhar², Joseph Merola³, Iain McInnes⁴, Deepak Assudani⁵, Rajan Bajracharya⁵, Jason Coarse⁶, Barbara Ink⁷ and Georg Schett⁸, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ²Oregon Health & Science University, Portland, OR, ³Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom, ⁵UCB Pharma, Slough, United Kingdom, ⁶UCB Pharma, Raleigh, NC, ⁷UCB Celltech, Slough, UK, Slough, United Kingdom, ⁸Universitätsklinikum Erlangen, Department of Internal Medicine 3 – Rheumatology and Immunology, Erlangen, Germany, Erlangen, Germany
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F and IL-17A, and has demonstrated clinical improvements in joint and skin outcomes…
Abstract Number: 1339 • ACR Convergence 2021
Treatment Persistence Was Similar at 3 Years in Patients with Psoriatic Arthritis Treated with Ustekinumab (STELARA®) or a Tumor Necrosis Factor Inhibitor in a Prospective Real-World Study
Laure Gossec¹, Stefan Siebert², Paul Bergmans³, Kurt de Vlam⁴, Elisa Gremese⁵, Beatriz Joven-Ibáñez⁶, Tatiana Korotaeva⁷, Wim Noël⁸, Michael Nurmohamed⁹, Petros Sfikakis¹⁰, Elke Theander¹¹ and Josef Smolen¹², ¹Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, ²University of Glasgow, Glasgow, United Kingdom, ³Janssen-Cilag BV, Breda, Netherlands, ⁴University Hospitals Leuven, Leuven, Belgium, ⁵Fondazione Policlinico A Gemelli-IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy, ⁶University Hospital 12 de Octubre, Madrid, Spain, ⁷VA Nasonova Research Institute of Rheumatology, Moscow, Russia, ⁸Janssen Pharmaceutica, HEMAR Department, Beerse, Belgium, ⁹Reade and Amsterdam University Medical Center, location VUmc, Amsterdam, Netherlands, ¹⁰National Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, ¹¹Janssen Cilag, Lund, Sweden, ¹²Medical University of Vienna, Vienna, Austria
Background/Purpose: Several options exist in the treatment of PsA, but data on long-term persistence are rare. Here, we assess long-term persistence with ustekinumab (UST) or…
Abstract Number: 1340 • ACR Convergence 2021
Upadacitinib Effects on Entheseal Domain in Psoriatic Arthritis Patients – a Pooled “post-hoc” Analysis from Two Phase III Studies (Select PsA 1 and 2)
Fabrizio Cantini¹, Antonio Marchesoni², Francesca Marando³, Giuliana Gualberti³, Lucia Novelli³, Giacomo Curradi³, Erin McDearmon-Blondell⁴, Tianming Gao⁵ and Carlo Salvarani⁶, ¹Department of Rheumatology, Azienda USL Toscana Centro, Hospital of Prato, Prato, Italy, ²Dipartimento di Reumatologia, ASST Gaetano Pini-CTO, Milano, Italy, ³AbbVie, Rome, Italy, ⁴AbbVie Inc., Elmhurst, IL, ⁵AbbVie Inc., North Chicago, IL, ⁶Unità Operativa di Reumatologia, Azienda USL-IRCCS di Reggio Emilia, Italy, Reggio Emilia, Italy
Background/Purpose: Reaching control or improvement on enthesitis domain in psoriatic arthritis (PsA) is challenging, and it continues to be a priority for patients (pts) and…
Abstract Number: 1341 • ACR Convergence 2021
Ixekizumab Shows a Pattern of Pain Improvement in Patients with and Without Measurable Inflammation in Psoriatic Arthritis
Kurt de Vlam¹, Gaia Gallo², Philip Mease³, Proton Rahman⁴, Venkatesh Krishnan², David Sandoval², Chen Yen Lin², Danting Zhu², Rebecca Bolce² and Philip Conaghan⁵, ¹University Hospitals Leuven, Leuven, Belgium, ²Eli Lilly and Company, Indianapolis, IN, ³Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ⁴Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: The efficacy of ixekizumab (IXE) and adalimumab (ADA) in patients with psoriatic arthritis (PsA) has been previously reported using ACR 50 and Psoriasis Area…
Abstract Number: 1342 • ACR Convergence 2021
Low Incidence of Gastrointestinal-related and Overall Serious Adverse Events Among Guselkumab-treated Patients: Pooled Analyses of VOYAGE 1 & 2 and DISCOVER 1 & 2 Through 1-Year
Philip Mease¹, Peter Foley², Kristian Reich³, Jerry Bagel⁴, Mark Lebwohl⁵, Ya-Wen Yang⁶, May Shawi⁷, Megan Miller⁸, Alexa Kollmeier⁹, Elizabeth Hsia⁸, Xie Xu⁸, Miwa Izutsu¹⁰, Paraneedharan Ramachandran¹⁰, Shihong Sheng⁸, Yin You⁸, Philip S Helliwell¹¹ and Wolf-Henning Boehncke¹², ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ²University of Melbourne, Carlton, Australia, ³University Medical Center Hamburg-Eppendorf, Hamburg, Germany, ⁴Psoriasis Treatment Center of Central New Jersey, Department of Dermatology, East Windsor, NJ, USA, East Windsor, NJ, ⁵Icahn School of Medicine at Mount Sinai, New York, NY, ⁶Janssen Global Services, LLC, Horsham, PA, ⁷Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, ⁸Janssen Research & Development, LLC, Spring House, PA, ⁹Janssen Research & Development, LLC, La Jolla, CA, ¹⁰Janssen Research & Development, LLC, Immunology, Spring House, PA, ¹¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ¹²Geneva University Hospitals, Geneva, Switzerland
Background/Purpose: Guselkumab (GUS), an anti-interleukin (IL)-23p19-subunit mAb, demonstrated efficacy in VOYAGE (VOY) 1&2 patients (pts) with moderate to severe plaque psoriasis (PsO)1,2 and in DISCOVER…
Abstract Number: 1343 • ACR Convergence 2021
Guselkumab Treatment Modulates Core Psoriatic Arthritis Gene Expression in Two Phase 3 Clinical Trials (DISCOVER-1 and -2)
Stefan Siebert¹, Kristen Sweet², Christopher Ritchlin³, Elizabeth Hsia⁴, Alexa Kollmeier⁵, Xie Xu⁴, Qingxuan Song² and Michelle Miron², ¹University of Glasgow, Glasgow, United Kingdom, ²Janssen Research & Development LLC, Spring House, PA, ³Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Janssen Research & Development, LLC, La Jolla, CA
Background/Purpose: Guselkumab (GUS), an anti-IL-23 p19-subunit monoclonal antibody, demonstrated efficacy vs placebo (PBO) in reducing signs and symptoms of PsA in the phase-3 DISCOVER-1 &…
Abstract Number: 1344 • ACR Convergence 2021
Impact of Achieving Minimal Disease Activity on Patient-Reported Outcome Measures and Disease Activity Among Patients with Psoriatic Arthritis Treated with Biologic and Targeted Synthetic DMARDs
Alexis Ogdie¹, Robert McLean², Maya Marchese², Taylor Blachley², Laura Anatale-Tardiff³, Christopher Saffore⁴, Kevin Douglas⁵, Danny Quach⁵ and Philip Mease⁶, ¹University of Pennsylvania, Philadelphia, PA, ²CorEvitas, LLC, Waltham, MA, ³CorEvitas, Waltham, MA, ⁴AbbVie, North Chicago, IL, ⁵AbbVie Inc., North Chicago, IL, ⁶Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA
Background/Purpose: Minimal disease activity (MDA) is a common goal for disease control when managing PsA. The aim of this study was to assess the association…
Abstract Number: 1345 • ACR Convergence 2021
Long-Term Safety and Effectiveness of Upadacitinib in Patients with Psoriatic Arthritis: Results at 56 Weeks from the SELECT-PsA 1 Study
Iain McInnes¹, Koji Kato², Marina Magrey³, Joseph Merola⁴, Mitsumasa Kishimoto⁵, Cesar Pacheco Tena⁶, Derek Haaland⁷, Liang Chen⁸, Yuanyuan Duan⁹, Patrick Zueger¹⁰, Jianzhong Liu¹¹, Ralph Lippe¹², Aileen Pangan¹¹ and Frank Behrens¹³, ¹University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom, ²AbbVie Inc, Shinagawa- Ku, Japan, ³Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, USA, Richfield, OH, ⁴Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, ⁵Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Yokohama, Japan, ⁶Facultad de Medicina, Universidad Autonoma de Chihuahua, Chihuahua, Mexico, ⁷McMaster University, Hamilton, Ontario and The Waterside Clinic, Oro Medonte, ON, Canada, ⁸AbbVie Inc., North Chicago, ⁹AbbVie Inc, North Chicago, ¹⁰AbbVie Inc., Mettawa, IL, ¹¹AbbVie Inc., North Chicago, IL, ¹²AbbVie Deutschland GmbH & Co. KG, Berlin, Germany, ¹³Rheumatology & Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Fraunhofer Cluster Immune-Mediated Diseases (CIMD), Fraunhofer Cluster Immune-Mediated Diseases (CIMD), Frankfurt/Main, Germany
Background/Purpose: In the SELECT-PsA 1 study, through 24 weeks (wks), once daily upadacitinib 15 mg (UPA15) and 30 mg (UPA30) showed improvements in musculoskeletal symptoms,…
Abstract Number: 1346 • ACR Convergence 2021
Comparable Safety Profile of Guselkumab in Psoriatic Arthritis and Psoriasis: Results from Phase 3 Trials Through 1 Year
Proton Rahman¹, Alice Gottlieb², Joseph Merola³, April Armstrong⁴, Richard Langley⁵, Mark Lebwohl², Christopher Griffiths⁶, May Shawi⁷, Ya-Wen Yang⁸, Elizabeth Hsia⁹, Alexa Kollmeier¹⁰, Xie Xu⁹, Miwa Izutsu¹¹, Paraneedharan Ramachandran¹¹, Shihong Sheng⁹, Yin You⁹, Megan Miller⁹, Christopher Ritchlin¹² and Iain McInnes¹³, ¹Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ²Icahn School of Medicine at Mount Sinai, New York, NY, ³Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Keck School of Medicine, University of Southern California, Clinical Research, Los Angeles, CA, ⁵Dalhousie University, Division of Clinical Dermatology & Cutaneous Science, Halifax, NS, Canada, ⁶University of Manchester, Manchester Centre for Dermatology Research, Manchester, United Kingdom, ⁷Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, ⁸Janssen Global Services, LLC, Horsham, PA, ⁹Janssen Research & Development, LLC, Spring House, PA, ¹⁰Janssen Research & Development, LLC, La Jolla, CA, ¹¹Janssen Research & Development, LLC, Immunology, Spring House, PA, ¹²Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, ¹³University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom
Background/Purpose: DISCOVER 1&2 (PsA) and VOYAGE 1&2 (psoriasis [PsO]) are Phase 3 trials of guselkumab (GUS). Here we compared safety results through up to 1…
Abstract Number: 1347 • ACR Convergence 2021
Ixekizumab Efficacy in Patients with Psoriatic Arthritis Presenting with Symptoms Indicative of Axial Involvement
Atul Deodhar¹, Dafna Gladman², Rebecca Bolce³, David Sandoval³, So Young Park³, Soyi Liu-Leage⁴, Peter Nash⁵ and Denis Poddubnyy⁶, ¹Oregon Health & Science University, Portland, OR, ²Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³Eli Lilly and Company, Indianapolis, IN, ⁴Eli Lilly and Company, Neuilly sur Seine, France, ⁵Griffith University, Brisbane, Australia, ⁶Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany
Background/Purpose: Many patients with psoriatic arthritis (PsA) experience back pain and stiffness indicative of axial involvement [1]. The prevalence of axial involvement varies between 25-70%…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].